Skip to main content

Use of Multiple Sclerosis Drugs Among Pregnant Women with Live-Birth Deliveries: A Descriptive Analysis

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    alemtuzumab
    cladribine
    dalfampridine
    dimethyl fumarate
    diroximel fumarate
    fingolimod
    glatiramer acetate
    interferon beta-1A
    interferon beta-1B
    mitoxantrone
    natalizumab
    ocrelizumab
    peginterferon beta-1a
    siponimod
    teriflunomide
    Description

    In this report we describe exposure to multiple sclerosis (MS) drugs before, during and after pregnancies resulting in a live-born delivery among women in the Sentinel Distributed Database (SDD). We also describe MS drug use among matched women during episodes without evidence of a live-birth delivery.

    The study period includes data from January 1, 2001 to December 31, 2020. We distributed this request to six Sentinel Data Partners on June 25, 2021.

    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2001- December 31, 2020
    Analysis Type
    Descriptive
    Population / Cohort
    Females 10 to 49 years of age
    Data Sources
    Sentinel Distributed Database (SDD)